NorthWest Biotherapeutics Inc (NWBO)

[f3tt3f]

The total amount will surely depend on how much tumor they had access to for manufacturing the vaccine.
i.e.
Placebo arm patient-X may only have had the minimum amount of tumor for the trial (presumably around double the amount required for the treatment protocol in case of early crossover?)
and treatment arm patient-Y may have enough tumor to create more than needed. So I don't think clinics should be able to tell who is in what arm by how much vaccine is left. Each will have different amounts (but still enough to get them through the crossover treatment, if needed)